Research programme: neuronal nitric oxide synthase inhibitors - GuilfordAlternative Names: Neuronal nitric oxide synthase inhibitors research programme - Guilford
Latest Information Update: 22 Dec 2000
At a glance
- Originator MGI GP
- Mechanism of Action Nitric oxide synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuroprotection
Most Recent Events
- 22 Dec 2000 Discontinued-Preclinical for Neuroprotection in USA (Unknown route)
- 26 Mar 1998 Preclinical development for Neuroprotection in USA (Unknown route)